Emergent partners with Asimov on antibody development
The collaboration aims to accelerate novel antibody candidates that could strengthen preparedness against evolving biological threats and help save lives.
See the latest news and media coverage for Emergent. We track all announcements, press releases, and industry mentions in real time, all in one place.
Specialty life sciences company focused on public health preparedness
emergentbiosolutions.comLast updated
In short: Emergent BioSolutions lowered 2026 sales guidance, secured a $22.3 million supply option, and partnered on Ebola antibodies.
The collaboration aims to accelerate novel antibody candidates that could strengthen preparedness against evolving biological threats and help save lives.
The modification falls under an existing delivery order with the U.S. Department of War. First delivery, worth about $7.4 million, starts this year, with the rest expected in 2027.
The company seeks candidates for manufacturing, technical, and operational roles to support public health initiatives at its new location.
Frank Vargo becomes interim CFO effective December 31, 2026, following Lindahl's departure after exceptional leadership.
Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.
Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $645.000 million-$675.000 million...
Emergent BioSolutions faces a sharp reset in 2026 guidance, with revenue projected at $720–$760 million, well below prior expectations. 2025 profitability was buoyed by favorable...
Emergent BioSolutions drops 8% after Q4 revenue miss and weak 2025 guidance. Read more here.
Track Emergent and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Emergent and other trending companies.